Oncolytics Biotech (ONCY) Net Margin (2009 - 2025)

Oncolytics Biotech's (ONCY) quarterly Net Margin came in at 14617.35% in Q3 2025, up 4979084.0% year-on-year from N/an in Q3 2024, and up 141.56% on a QoQ basis from 35173.48% in Q3 2024.

Oncolytics Biotech (ONCY) Net Margin (2009 - 2025) Analysis & Trends

Oncolytics Biotech (ONCY) has 10 years of Net Margin data on file, last reported at 14617.35% in Q3 2025.

  • On a quarterly basis, Net Margin rose 4979084.0% year-over-year to 14617.35% in Q3 2025; TTM through Sep 2025 was 32.38%, a 1750.0% decrease from a year earlier, with the FY2018 full-year figure at 125.74%, changed N/A from the prior year.
  • Net Margin for Q3 2025 stood at 14617.35%, up from 35173.48% in the prior quarter.
  • Over the last five years, Net Margin for ONCY reached as high as 14617.35% in Q3 2025 and fell as low as 35173.48% in Q3 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 15.02%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 34.53%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 20.17%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 30.33%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Oncolytics Biotech 372.40 Mn 372.40 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 14,617.35%
Sep 30, 2024 -35,173.48%
Sep 30, 2020 -16.37%
Jun 30, 2020 -14.53%
Mar 31, 2020 1,156,663.68%
Sep 30, 2019 -28.38%
Jun 30, 2019 -43.33%
Mar 31, 2019 -34.75%
Dec 31, 2018 34.09%
Sep 30, 2018 20,878.15%
Jun 30, 2017 0.00%
Jun 30, 2016 381.71%
Jun 30, 2011 520.98%
Sep 30, 2010 2,106.77%
Jun 30, 2010 -623.44%
Sep 30, 2009 27.90%
Jun 30, 2009 36.17%
Mar 31, 2009 42.59%